A Study to Evaluate the Efficacy and Safety of Abiprubart in Participants With Sjögren's Disease

PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

July 17, 2024

Primary Completion Date

March 6, 2025

Study Completion Date

May 1, 2025

Conditions
Sjögrens Disease
Interventions
DRUG

Abiprubart

humanized monoclonal antibody

DRUG

Placebo

sterile preservative-free solution

Trial Locations (16)

28144

Accellacare (Salisbury), Salisbury

28401

Carolina Arthritis Associates, Wilmington

32117

International Medical Research, Daytona Beach

32713

Omega Research Debary, LLC, DeBary

60076

Clinic of Robert Hozman, MD/Clinical Investigation Specialists, Inc., Skokie

60195

Greater Chicago Specialty Physicians/ Clinical Investigation Specialists, Schaumburg

62702

Springfield Clinic Rheumatology, Springfield

70605

Accurate Clinical Research, Inc, Lake Charles

75013

Arthritis and Rheumatology Research Institute, PLLC, Allen

75024

Trinity Universal Research Associates, Inc., Plano

76710

Arthritis & Osteoporosis Clinic, Waco

78215

Sun Research Institute, San Antonio

78415

Arthritis Care of Texas, Corpus Christi

90602

Medvin Clinical Research, Whittier

92064

BioSolutions Clinical Research Center, Poway

92586

Medvin Clinical Research, Menifee

All Listed Sponsors
collaborator

Kiniksa Pharmaceuticals, GmbH

INDUSTRY

lead

Kiniksa Pharmaceuticals International, plc

INDUSTRY

NCT06531395 - A Study to Evaluate the Efficacy and Safety of Abiprubart in Participants With Sjögren's Disease | Biotech Hunter | Biotech Hunter